ESR1 and breast carcinoma: The expression of biomarkers, too, was consistent with human breast cancers resulting in a poor prognosis, with a gradual loss in ER, progesterone receptor, as well as integrin-β1 along with the persistent expression of cyclin-D1 and ErbB2/Neu (equivalent to human HER2).